Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,351 matching trials from the live ClinicalTrials.gov search.

Filters: New Haven, Connecticut Clear all

Conditions: Heart Transplant
Interventions: Transplant; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Healthy Adults
Interventions: PF-07248144; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Peripheral Artery Disease
Interventions: Lutonix Drug Coated Balloon; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 39
States / cities: Los Angeles, California • Oceanside, California • Orange, California + 32 more

Conditions: Necrotizing Soft Tissue Infections, Necrotizing Fasciitis, Fournier's Gangrene
Interventions: AB103 0.5 mg/kg, NaCl 0.9%; Drug · Other
Lead sponsor: Atox Bio Ltd; Industry
Eligibility: 12 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Type 1 Diabetes
Interventions: Virtual home intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 14 Years to 19 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: GERD
Interventions: Controls & Cases; Other
Lead sponsor: Loren Laine; Other
Eligibility: 21 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C), Test formulation (Treatment D); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Osteogenesis Imperfecta
Interventions: Setrusumab, Placebo; Biological · Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 5 Years to 25 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more

Conditions: Spine Degeneration, Hip Arthritis, Knee Osteoarthritis, Hip Fractures
Interventions: App for in-bed conditioning exercises, Usual care; Device · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions: Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 55
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 42 more

Conditions: Meningioma
Interventions: JZP3507; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 8
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 5 more

Conditions: Atrial Fibrillation
Interventions: Apixaban, Acetylsalicylic acid; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 50 Years and older
Enrollment: 6,421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 69
States / cities: Mobile, Alabama • Tucson, Arizona • Anaheim, California + 62 more

Conditions: Bronchiolitis Acute Viral
Interventions: Educational Outreach, Audit & Feedback (unit level), Audit & Feedback (real time, individual-level), Clinical Pathway Integrated into Electronic Health Record; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months and older
Enrollment: 9,265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Davis, California • Encinitas, California + 42 more

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Disitamab vedotin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 120
States / cities: Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 96 more

Conditions: Myelodysplastic Syndromes
Interventions: Imetelstat Sodium, Placebo; Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 22
States / cities: Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more

Conditions: Respiratory Depression
Interventions: Expiron respirator; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Myelodysplastic Syndromes
Interventions: Tebapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 9
States / cities: Lakewood, California • Los Angeles, California • Redlands, California + 6 more

Conditions: Alcohol Drinking, Marijuana
Interventions: Text Messaging and Brief Negotiation Interview; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 2
Interventions: Nutrition visits, Intensification of diabetes regimen, Continuous glucose monitor (CGM); Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: PF-06480605, Placebo; Drug
Lead sponsor: Telavant, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Depression, Cognition, Quality of Life
Interventions: Digital neurotherapy (DNT) Treatment, Wait list control group; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: routine HIV testing; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: New Haven, Connecticut • Niantic, Connecticut

Conditions: Femoral Arterial Calcification, Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
Interventions: Shockwave Intravascular Lithotripsy (IVL); Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Providence, Rhode Island

Conditions: Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions: Palifermin; Drug
Lead sponsor: Brett King; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Bridgeport, Connecticut • New Haven, Connecticut

Search by objective public record fields.

Donor After Circulatory Death Heart CAP Trial

A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults

LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB)

Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections

Virtual Physical Activity for Type 1 Diabetes

Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease

A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

Setrusumab vs Placebo for Osteogenesis Imperfecta

Evaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

Eliminating Monitor Overuse Trial (EMO Trial)

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Detection of Postoperative Respiratory Depression in High Risk Patients Utilizing Minute Ventilation Monitoring

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Brief Interventions With Text Messaging to Reduce Adolescent Alcohol and Marijuana Use

Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

Feasibility and Efficacy of a Digital Neurotherapy Protocol for Management of Depression, Cognition, and Quality of Life in Cancer Survivors

Early Versus Delayed Routine HIV Testing in Connecticut Jails

CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis